Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

237
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
237
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

761
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
761
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids01:24

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

187
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
187
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

2.9K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
2.9K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

2.5K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.5K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

799
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
799

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comprehensive Evaluation of Indazole-Based Synthetic Cannabinoid Receptor Agonists with Aliphatic Tail Groups: In Vitro Activities, Metabolic Stability, and In Vivo Pharmacokinetics.

ACS chemical neuroscience·2026
Same author

Author Correction: Acoustic metamaterials-driven transdermal drug delivery for rapid and on-demand management of acute disease.

Nature communications·2026
Same author

Cannabidiol attenuates chemotherapy-induced peripheral neuropathic pain through a mechanism that requires the enzyme <i>N</i> -acylphosphatidylethanolamine-specific phospholipase D (NAPE-PLD).

bioRxiv : the preprint server for biology·2026
Same author

Short-Term Safety and Adverse Event Risk Profiles for SARS-CoV-2 Booster Vaccine Doses in Australian Adults: A Survey Study.

The Medical journal of Australia·2026
Same author

Don't Sweat It: Cannabinoid CB1 Receptors Reduce Sweating in a Mouse Model.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2026
Same author

Associations between specialty registered nurse certification and patient outcomes: A nurse-patient-level analysis.

Nursing outlook·2026

Related Experiment Video

Updated: Jun 27, 2025

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

8.9K

CB1 Receptor Negative Allosteric Modulators as a Potential Tool to Reverse Cannabinoid Toxicity.

Audrey Flavin1, Paniz Azizi1, Natalia Murataeva1

  • 1Gill Center for Biomolecular Science, Program in Neuroscience, Department of Psychological and Brain Sciences Indiana University, Bloomington, IN 47405, USA.

Molecules (Basel, Switzerland)
|April 27, 2024
PubMed
Summary

New negative allosteric modulators (NAMs) show promise in reversing synthetic cannabinoid toxicity. These compounds effectively counter potent synthetic cannabinoids like JWH018 without causing withdrawal, offering a potential antidote.

Keywords:
JWH018antidotecannabinoid toxicityoverdosesynthetic cannabinoid

More Related Videos

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

13.6K
Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies
05:25

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies

Published on: December 29, 2021

2.5K

Related Experiment Videos

Last Updated: Jun 27, 2025

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

8.9K
Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

13.6K
Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies
05:25

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies

Published on: December 29, 2021

2.5K

Area of Science:

  • Pharmacology
  • Neuroscience
  • Toxicology

Background:

  • Emergency room visits for cannabinoid toxicity are rising, driven by potent synthetic cannabinoids.
  • Unlike opioid overdoses, there is no specific antidote for cannabinoid toxicity.
  • Current treatments for cannabinoid toxicity include supportive care or sedatives, which have risks.

Purpose of the Study:

  • To investigate the potential of CB1 receptor negative allosteric modulators (NAMs) as an antidote for synthetic cannabinoid toxicity.
  • To evaluate the efficacy of specific CB1 NAMs (ABD1085, RTICBM189, PSNCBAM1) in reversing the effects of JWH018, a potent synthetic cannabinoid.

Main Methods:

  • In vitro testing on autaptic hippocampal neurons to assess the reversal of JWH018 effects on endogenous cannabinoid signaling.
  • In vivo testing in mice using a nociception assay to evaluate the blockade of JWH018 effects.
  • Assessment of PSNCBAM1 for its ability to reverse JWH018 effects when administered post-exposure and its effect on withdrawal symptoms after chronic JWH018 treatment.

Main Results:

  • All tested CB1 NAMs (ABD1085, RTICBM189, PSNCBAM1) reversed JWH018 effects in vitro, with varying potency.
  • In vivo, only RTICBM189 and PSNCBAM1 blocked JWH018 effects when administered preventatively; in vitro potency did not predict in vivo efficacy.
  • PSNCBAM1 demonstrated higher potency in vivo, reversed JWH018 effects post-administration, and did not induce withdrawal after chronic JWH018 exposure.

Conclusions:

  • CB1 NAMs can effectively reverse the toxic effects of the synthetic cannabinoid JWH018 both in vitro and in vivo.
  • PSNCBAM1 shows particular promise as a potential antidote for synthetic cannabinoid toxicity due to its potency and lack of withdrawal induction.
  • These findings suggest a novel pharmacological strategy for managing cannabinoid toxicity.